
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Overview | Financials
Company Name | BioMarin Pharmaceutical Inc. |
Symbol | BMRN |
Currency | USD |
Price | 70.6 |
Market Cap | 13,468,856,200 |
Dividend Yield | 0% |
52-week-range | 60.63 - 94.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jean-Jacques Bienaime M.B.A., MBA |
Website | https://www.biomarin.com |
An error occurred while fetching data.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD